Posted by Michael Wonder on 04 Dec 2020
Proposal to widen access to rituximab for treatment of membranous nephropathy
4 December 2020 - PHARMAC is seeking feedback on a proposal to widen access to rituximab.
PHARMAC is seeking feedback on a proposal to widen access to rituximab from 1 March 2021 for the treatment of membranous nephropathy in patients at high risk of progression to end-stage kidney disease despite conservative measures.
